INTRODUCTION
Pheochromocytoma (PHEO) and paraganglioma (PGL) are rare neuroendocrine tumors in children. In 2004, World Health Organization (WHO) defined PHEO as a tumor arising from catecholamineproducing chromaffin cells in the adrenal medulla (an intra-adrenal PGL) 1 . Tumors arising from extra-adrenal sympathetic and parasympathetic paraganglia are defined as extra-adrenal PGLs, commonly found in the head, neck, and abdomen 1 . By WHO definition, PHEO and PGL are closely related, and are classified in terms of location. In children, incidence of PHEO and PGL is estimated at 0.3 cases per million a year or less 2 , and approximately 10-20% of PHEO and PGL are diagnosed during childhood at an average age of 11 years 3 .
Malignant PHEO and PGL are defined as the presence of distant metastasis 1 . Although the rate of malignancy is known as 10% 4 , malignancy rate varies within the literature and may be as high as 26 % 5 . Because of unfavorable prognosis and lack of definite curative treatment for malignant PHEO and PGL, prediction of malignancy and early detection of metastasis are important for treatment and follow-up. But currently malignant PHEO and PGL lack histological or molecular markers that reliably distinguish them from benign tumors.
Thompson LD created the Pheochromo- However, the patients enrolled in that study were mainly adults, and its applicability to pediatric patients has not been established. Some immunohistochemical markers such as Ki-67, p53, bcl-2, mdm2, cyclin D1, p21, and p27 have been reported as potential tools to differentiate malignant from benign PHEO 8-10 . Since Ki-67 is found throughout the cell cycle except in resting cells (G0 phase) 11 , it can be used to evaluate the growth rate of tumors, and several studies have been demonstrated correlation between high Ki-67 positivity rate and malignancy 9, 12, 13 .
Because the features of diseases including clinicopathologic profiles, treatment, and clinical outcomes are poorly characterized in the pediatric literature, we designed this study to review clinical features of malignant PEHO and abdominal PGL (aPGL), to validate PASS as a prognostic indicator of malignant PHEO and aPGL in children, and to document risk factors of malignancy in patients with PHEO or aPGL.
PATIENTS AND METHODS
We reviewed the database from medical records of 20 patients (≤18 years of age) with pathologically confirmed PHEO or aPGL after surgical resection by 3 surgeons (14, 3, and 3 operations, respectively) at Seoul National University Children's Hospital between January 1990 and December 2010. With this prospectively collected database, demographics, symptoms, signs, results of laboratory test, treatment information, pathologic results, and outcomes were obtained. Follow-up monitoring was accomplished through recent clinic visits and telephone correspondence. Patients were monitored until they died or we lost contact with them. Malignancy of PHEO and aPGL was defined as the presence of distant metastasis such as bone, liver, and lung 1 . The tumor which was recurred distantly after complete resection was also regarded as malignant. Only PHEO and PGL in the abdominal cavity were included, and PGL in the head and neck was excluded in this study.
To confirm diagnosis and to assess PASS score, all pathologic slides were reviewed by a single endocrinologic pathologist blinded to the clinical data. Overall PASS score was calculated according to their microscopic features. After obtaining five-micron sections from the paraffin-embeded tissue block, we stained these sections with hematolxylin and eosin to identify representative areas of PHEO and aPGL in such tissue block. After identification of representative area, core biopsies (2mm in diameter) were taken from tissue block and arranged in a new recipient paraffin block using a tissue microarray device (Trephine Apparatus, Superbiochips Laboratories, Seoul, Korea). The antibodies used for immunohistochemistry included mouse human monoclonal antibodies to mdm-2, p21, p53, Ki-67, and bcl-2, and rabbit polyclonal antibodies to Cyclin D1 and p27. For all antibodies, heat-induced epitope retrieval was performed using selected buffer solution ( Table 1 ). The immuno-histochemical staining was processed with Leica BOND-MAX TM autostainer 14 .
An endocrinologic pathologist, who reviewed pathologic slides, also reviewed and scored each immunostain. The percentage of tumor cells showing characteristic staining was measured in a semiquantitative manner. Cutoff values for immunohistochemical stain were established (Table 1) 15 .
Descriptive statistics were used to provide a summary of the data. Fisher' s exact test, Student' s t-test, Mann-Whitney test were used for comparative statistical analysis. The Kaplan-Meier method to estimate overall survival and the log-rank test to compare overall survival were used between benign and malignant PHEO and 장지훈 외：소아에서 갈색세포종과 복강내 부교감신경절종의 악성화 예측인자 111 Table 2) .
Analysis between benign and malignant tumors showed no difference in age, In the analysis between benign and malignant PHEO and aPGL, vascular 장지훈 외：소아에서 갈색세포종과 복강내 부교감신경절종의 악성화 예측인자 113 (Table 4 ). In the subgroup analysis of patients with PHEO, these pathologic profiles were also significantly frequent in malignancy (p=.033, . 003, and .019, respectively). Presence of large nests and nuclear hyperchromasia were more .008, respectively) ( Table 5 ). In the aPGL subgroup, there was no statistical difference in pathologic profiles between benign and malignant tumors. Although mean PASS score of PHEO and aPGL was slightly higher in patients with malignancy, there was no significant difference in mean PASS score of PHEO and aPGL between benign and malignant patients (p=.317). Five of seven patients with malignant tumors and 10 of 13 patients with benign tumors showed PASS ≥ 4 (Table 6 ).
To predict malignancy of PHEO and aPGL in pediatric patients, a new pathologic score system was created using these significant pathologic profiles, vascular invasion (2 points), extension into adipose tissue (3 points), and increase in mitotic count (1 point). With this system, score of patients with malignancy was significantly higher (p=.001) ( Table 6 ). There is significant difference between benign and malignant tumor with cutoff value of 2, and its sensitivity is 71.4% and specificity is 92.3%.
In respect to immunohistochemical 장지훈 외：소아에서 갈색세포종과 복강내 부교감신경절종의 악성화 예측인자 115 markers, Ki-67, p53, bcl-2, mdm-2, cyclin D1, p21, and p27 did not show significant difference and failed to predict malignancy (Table 7) . There was no over-expression of cyclin D1 in both benign and malignant groups. In the subgroup analysis of PHEO and aPGL, immunohistochemistry showed no difference between benign and malignant patients.
DISCUSSION
PHEO and PGL are rare neuroendocrine tumors in children and the majority is benign. Because the prognosis of malignant PHEO and PGL is poor, many studies have tried to demonstrate risk factors of malignancy. This study was designed to investigate the clinico-pathologic features of malignant PHEO and aPGL, to validate PASS as a prognostic indicator of malignancy in pediatric patients, and to document risk factors of malignancy.
Clinical features showed no difference between PHEO and aPGL, and between benign and malignant tumors. Only postoperative adjuvant radiotherapy was significantly frequent in malignancy. Malignancy rate in this study population was 35%, and was higher than that for other pediatric population 1 and for adults 5, 16 . 28.6% of PHEO and 50% of aPGL were malignant, and these results corresponded well with those of the study reporting that sympathetic PGL showed greater risk of malignant transformation 4, 17 . Although hypertension, palpitation, and headache are the three most common symptoms and signs in this study, similar to the presentation in adults 18, 19 , clinical manifestations demonstrate no difference between benign and malignant PHEO and aPGL. Primary tumor size and location showed no role in predicting malignancy, in contrast to the results of study reporting primary tumor size and location as prognostic indicators 20 .
Some pathologic profiles such as cellular atypia, capsular or vascular invasion, or areas resembling pediatric neuroblastoma have been proposed as prognostic factors in some literature 1, 21 . In this study, pathologic profiles, vascular invasion, extension into peritumoral adipose tissue, and increased mitotic count, indicate significant correlation with malignancy in PHEO and aPGL. Thompson Without prospective validation, PASS has been used to report pathologic results and to predict clinical prognosis. PASS was not validated in the study with pediatric population. PASS score more than four has suggested risk of malignant transformation 6, 7 . However, this study revealed no difference in mean PASS score between benign and malignant PHEO and aPGL. Five of seven patients with malignant tumors and 10 of 13 patients with benign tumors showed PASS ≥ 4. Five of seven patients with malignant and 8 of 13 patients with benign tumors showed PASS ≥ 6.
With cutoff value of 4 and 6, PASS cannot predict malignancy in this pediatric population. Thompson LD 6 and Strong et al 7 demonstrated significance of PASS in mostly adult population, whereas our results did not show any difference in pediatric population. Interestingly, in the subgroup analysis of patients with PHEO, the pathologic profiles such as presence of large nests and nuclear hyperchromasia were more frequent in benign tumor. These findings suggest that some of pathologic profiles included in PASS system cannot be used to predict malignancy in certain pediatric population.
Moreover, Wu et al have found significant interobserver and intraobserver variation in assignment of PASS with variable interpretation of the underlying components 22 . Therefore, PASS system needs to be refined, prospectively validated, and strengthened by new markers of immunohistochemistry and molecular biology in pediatric population.
In this study, we created the new pathologic scoring system to predict malignancy of PHEO or aPGL. In the new pathologic score system using extension into peritumoral adipose tissue (3 points), vascular invasion (2 points), and increased mitosis (1 point), mean score is significantly higher in malignancy. This scoring system was made taking into account the frequency of appearance of pathologic profiles in malignancy and benign. Designing many models for this scoring system, this point system showed the best results. With a cutoff value of 2, its sensitivity and specificity to predict malignancy showed best results, which were 71. 4% and 92.3%, respectively. Even though malignancy cannot be predicted clearly with this score system, the higher score can reflect malignancy.
With immunohistochemistry, some markers have been introduced to predict 장지훈 외：소아에서 갈색세포종과 복강내 부교감신경절종의 악성화 예측인자 117 prognosis of PHEO and PGL. Ki-67 has been considered as a proliferative marker and higher Ki-67 expression has been observed in malignant PHEO 9, 12, 13 . But high expression of Ki-67 is rarely observed in PHEO and sensitivity of Ki-67 is as low as 35% 9, 12, 13 . Most malignant PHEOs can show Ki-67 positivity rate less than 1% 6 . Such low Ki-67 expression rate indicates that PHEO and aPGL are growing slowly. Therefore, most authors have chosen a low cutoff value such as 2%. In this study, 15. 4% of benign and 57. 1% of malignant PHEO and aPGL showed Ki-67 high expression with this cutoff value (p=. 122). High expression rate of Ki-67 demonstrates that proliferation rate of pediatric malignant PHEO and aPGL is higher than that of malignant PHEO and aPGL in adults. Bcl-2 was over-expressed in 61.5% of benign and 57.1% of malignant PHEO and aPGL (p>.999), and these findings differ from the study reporting a significant correlation between benign and malignant PHEO 8 . Whereas cyclin D1 has been known to have a role in PHEO tumorigenesis 23 , no over-expression of cyclin D1 was demonstrated in benign and malignant PHEO and aPGL. p53, mdm-2, p21, and p27 were unable to predict malignant PHEO and aPGL in this study.
The retrospective nature of this study has some limitations including selection bias inherent in a tertiary referral hospital study. Limited number of cases can also give relatively low statistical power. The results of this study should be interpreted cautiously, and judicious introduction of the rates to general population may be necessary. Nevertheless, this study has multiple strengths. It is designed for pediatric patients, poorly described in the literature. PASS was validated with patients under age of 18 and its applicability of PASS to pediatric patients was established for the first time. Furthermore, this study contains relatively large case series on pediatric PHEO and aPGL, and most patients have had long-term follow-up 24-26 . CONCLUSION Vascular invasion, extension into peritumoral adipose tissue, and increased mitotic count are significant risk factors for malignancy of PHEO and aPGL in children. The newly designed pathologic score system using these pathologic factors can be used as a potential prognostic factor of malignancy. Ki-67, p53, bcl-2, mdm-2, cyclin D1, p21, and p27 show no role in predicting malignancy.
